Tibet AIM Pharm. Inc.

002826

CNE100002C39

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 03:30:00 16/07/2024 am IST			5-day change	1st Jan Change
7.78 ^CNY	-0.38%		-0.51%	-34.46%

03/07	Tranche Update on Tibet AIM Pharm. Inc.'s Equity Buyback Plan announced on October 30, 2023.	CI
27/05	Tibet Aim Pharm. Inc. Announces Final Dividend on A Shares for the Year 2023, Payable on 31 May 2024	CI

Tranche Update on Tibet AIM Pharm. Inc.'s Equity Buyback Plan announced on October 30, 2023.

July 04, 2024 at 01:02 am IST

From April 1, 2024 to June 30, 2024, the company has repurchased 3,203,800 shares, representing 1.72% for CNY 27.39 million. With this, the company has completed the repurchase of 7,203,800 shares, representing 3.81% for CNY 63.36 million under the buyback announced on October 30, 2023.

Latest news about Tibet AIM Pharm. Inc.

Tranche Update on Tibet AIM Pharm. Inc.'s Equity Buyback Plan announced on October 30, 2023.	04/07	CI
Tibet Aim Pharm. Inc. Announces Final Dividend on A Shares for the Year 2023, Payable on 31 May 2024	28/05	CI
Tibet AIM Pharm. Inc. Approves Cash Dividend for the Year 2023	21/05	CI
Tibet AIM Pharm. Inc. Proposes Final Cash Dividend for 2023	27/04	CI
Tibet AIM Pharm. Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	25/04	CI
Tranche Update on Tibet AIM Pharm. Inc.'s Equity Buyback Plan announced on October 30, 2023.	02/04	CI
Tranche Update on Tibet AIM Pharm. Inc.'s Equity Buyback Plan announced on October 30, 2023.	02/01	CI
Tibet AIM Pharm. Inc. announces an Equity Buyback for CNY 100 million worth of its shares.	29/23/29	CI
Tibet AIM Pharm. Inc. Reports Earnings Results for the Nine Months Ended September 30, 2023	29/23/29	CI
Tibet AIM Pharm. Inc. authorizes a Buyback Plan.	26/23/26	CI
Tibet AIM Pharm. Inc. Reports Earnings Results for the Half Year Ended June 30, 2023	22/23/22	CI
Tibet AIM Pharm. Inc. Announces Final Profit Distribution Plan to Be Implemented on A Shares for the Year 2022, Payable on 07 July 2023	01/23/01	CI
Tibet AIM Pharm. Inc. Approves Cash Dividend for 2022	20/23/20	CI
Tibet Aim Pharm. Inc. Proposes Final Cash Dividend for the Year 2022	28/23/28	CI
Tibet AIM Pharm. Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	26/23/26	CI
Tibet AIM Pharm. Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	17/23/17	CI
Tibet Aim Pharm Chairman Resigns; Successor Named	13/23/13	MT
Tibet Aim Pharm Unit to Buy 21% Stake in US Medtech Firm Pier 88 Health for $6 Million	13/23/13	MT
Tibet AIM Pharm. Inc. Reports Earnings Results for the Nine Months Ended September 30, 2022	27/22/27	CI
Tibet AIM Pharm. Inc. Reports Earnings Results for the Half Year Ended June 30, 2022	24/22/24	CI
Tibet Aim Pharm. Inc. Announces 2021 Final Profit Distribution Plan to Be Implemented (A Shares) for the Year 2021, Payable on 8 July 2022	02/22/02	CI
Tibet AIM Pharm. Inc. Approves 2021 Profit Distribution Plan	20/22/20	CI
Tibet AIM Pharm. Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	27/22/27	CI
Tibet AIM Pharm. Inc. Proposes Final Cash Dividend for the Year 2021	23/22/23	CI
Tibet AIM Pharm. Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	08/22/08	CI

Chart Tibet AIM Pharm. Inc.

Duration

Period

More charts

Company Profile

TIBET AIM PHARM INC is a China-based company principally engaged in the research, design, manufacture and distribution of chemical drugs and Chinese patent medicine. The Companyâs products include self-manufacturing medicine and third-party medicine. Self-manufacturing medicine includes miglitol tablets, hongjinxiaojie tablet, aceclofenac enteric-coated tablets, montmorillonite powder, as well as domperidone tablets, among others. Its third-party medicine includes gualoupi injection, nalmefene hydrochloride injection, oral liquid for children, cefotaxime sodium for injection, as well as carbetocin injection. The Company distributes its products within domestic market and to overseas markets.

Sector

Pharmaceuticals

Calendar

16/08/2024 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
TIBET AIM PHARM. INC.	-34.46%	20Cr
ELI LILLY AND COMPANY	+61.53%	85TCr
NOVO NORDISK A/S	+38.95%	63TCr
JOHNSON & JOHNSON	-3.66%	36TCr
MERCK & CO., INC.	+15.06%	32TCr
ABBVIE INC.	+9.18%	30TCr
ROCHE HOLDING AG	+5.89%	23TCr
NOVARTIS AG	+16.53%	23TCr
AMGEN INC.	+15.67%	18TCr
PFIZER, INC.	+2.47%	17TCr